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Summary and Key Points 
1. Multi-disciplinary team involvement is essential to the care of 
patients with Cancers of Unknown Primary (CUP). 
2. Most presentations of CUP have a poor prognosis, with median 
survival of 6-9 months. 
3. Similarly, axillary nodal metastasis pathologically consistent with 
breast cancer and undifferentiated carcinoma in the midline of the 
thorax in young males have a far better prognosis and are each 
managed differently with curative intent. 
 
Introduction 
Cancers of unknown primary (CUP) are a heterogeneous group of 
histologically proven metastatic tumors whose primary site can't be 
determined after a standard diagnostic and pathologic work-up. CUP 
accounted for 2% of all cancers diagnosed in the United States in 2009 
(estimated 31,490 cases).1 CUP occurs equally in men and women, most 
frequently in the sixth decade of life. Even with thorough investigation, a 
primary tumor is found in fewer than 30% of patients who initially present 
with CUP.2 
CUP can manifest with an unlimited variety of clinical presentations and 
have a poor prognosis in most patients. The median survival is 6-9 
months.3 Multiple sites of involvement are observed in more than 50% of 
patients. The most common sites of involvement include the liver, lungs, 
bones, and lymph nodes. Although patterns of metastases can suggest 
clues as to the primary tumor, CUP can metastasize to any site in the 
body, making the pattern of metastasis alone insufficient to determine 
the origin. Like most cancers, CUP possesses both favorable and 
unfavorable prognostic factors (Table 1).4 For these reasons, a thorough 
clinical and pathologic evaluation is essential for helping people 
diagnosed with CUP. 
 
 
Initial Evaluation 
As noted above, CUP is defined by the inability to determine a primary 
tumor site despite a standard diagnostic and pathologic evaluation. While 
different clinicians may select different approaches to any individual 
patient, this section and the following section on the pathologic 
evaluation of CUP are reasonable examples of standard evaluations. 
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Initial evaluation of a patient with suspected metastatic cancer involves a 
complete history and physical examination, including breast, 
genitourinary, pelvic and rectal examination. Special attention should 
also be paid to both the individual and family cancer history. 
All past biopsies, removed lesions or spontaneously regressing lesions 
should be reviewed, as should any previous imaging studies. Other 
important diagnostic tests include laboratory studies (complete blood 
count, electrolytes, liver function tests, creatinine, calcium and 
urinalysis); computed tomography (CT) scan of the chest, abdomen and 
pelvis; and heme-occult stool testing. Endoscopy should be employed as 
directed by clinical signs and symptoms or other diagnostic findings. 
Determining whether the malignancy is localized or disseminated is also 
important for treatment planning. Positron emission tomography (PET) 
and/or PET-CT scan is frequently used for this aspect of evaluating 
patients with metastatic disease. 
Biopsy is necessary to confirm the presence of malignancy. Core needle 
biopsy is the preferred method of biopsy, although fine needle aspiration 
or incisional biopsy, by an experienced surgical oncologist, are also 
options. Biopsy of the most easily attainable lesion is usually performed. 
A pathologist should be involved at the time of biopsy to confirm the 
adequacy of the specimen or to determine the need for more tissue if a 
biopsy was performed prior to presentation to the oncologist. 
Extensive pathologic analysis of the tumor is required to determine the 
site of the primary tumor. This type of evaluation will identify a primary 
site in about 30% of patients. Light microscopic examination is usually 
done first. CUP can be classified into four major subtypes following 
routine light microscopic evaluation: 
I. Well or moderately differentiated adenocarcinoma (60%) 
II. Poorly- or undifferentiated adenocarcinoma (30%) 
III. Squamous cell carcinoma (5%) 
IV. Poorly differentiated malignant neoplasm (5%).5 
Immunohistochemical (IHC) studies are used to help characterize the 
poorly- and un- differentiated tumors. For example, carcinomas are 
usually positive for the anti-cytokeratin antibody CAM5.2 and endomysial 
antibody (EMA), whereas melanoma is positive for S-100, and 
lymphomas and leukemias are positive for leucocyte common antigen 
(LCA). In addition, IHC studies are useful for the pathologic diagnosis of 
the occult primary tumor. For example, the low molecular weight 
cytokeratins CK7 and CK20 are the two most common immunostains 
used to define subsets of carcinomas. CK7 is usually found in tumors of 
the lung, ovary, endometrium and breast, whereas CK20 is found in 
lower gastrointestinal, urothelial and Merkel cell carcinomas.6 Combining 
the two immunostains can further narrow the differential diagnosis (Table 
2). 
 
Recently, gene expression profiling (GEP) has been used to identify 
metastatic carcinoma tissue of origin in patients with CUP. Both 
microarray and reverse transcriptase polymerase chain reaction (RT- 
PCR) assays have been used. The microarray technique measures the 
mRNA expression of more than 1,500 genes in the tumor tissue, and 
then compares the mRNA profile to established RNA tissue profiles. This 
technique has demonstrated an overall sensitivity of 87.8% and an 
overall specificity of 99.4%.7 One RT- PCR  assay measures the 
expression of 10-specific gene markers designed to detect tumor 
originating from lung, breast, colon, ovary, pancreas and prostate.8 This 
assay has an overall accuracy of 78%. While GEP looks promising, at 
this time prospective clinical trials are necessary to determine whether 
this approach can be used in choosing treatment options that will 
significantly improve the outcomes for patients with CUP. 
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There is some debate as to how much additional evaluation should be 
performed to search for the primary malignancy beyond the initial tests 
and pathologic evaluation. Most oncologists agree that it is reasonable to 
consider additional studies as indicated by the clinical and pathological 
situation, particularly if there is a chance of discovering a treatable 
primary such as breast cancer. For example, adenocarcinoma with 
positive axillary lymph nodes in a woman is highly suggestive of an 
occult breast primary, and evaluation with a breast MRI would be 
indicated. 
 
Treatment 
Caring for patients with CUP is one of the most challenging situations in 
oncology. Given the uniqueness of each patient’s situation, 
individualized, multimodality treatment approaches are essential. 
Involvement of a multi-disciplinary tumor board including medical 
oncologists, surgical oncologists, radiation oncologists, palliative care 
physicians, psychologists, pharmacists, social workers, case managers, 
chaplaincy, or other indicated specialists is particularly helpful. 
In a majority of patients, CUP is refractory to systemic chemotherapy and 
treatment is often only palliative. Establishing realistic goals of care with 
the patient and family is difficult but necessary, and patients should be 
informed of the availability of any appropriate clinical trials. 
Currently the National Cancer Center Network (NCCN) guidelines for 
occult primary cancers (their term for CUP) recommend that in patients 
with disseminated disease, treatment goals should be directed toward 
symptom control and ensuring the best quality of life. Chemotherapy 
should be limited to symptomatic patients with a reasonable performance 
status or asymptomatic patients with aggressive cancer histology. The 
choice of the regimen should be based on the histologic type of cancer. 
(Table 3)  
 
For localized disease, consultation with a surgical oncologist should be 
obtained to determine a potential therapeutic or palliative role for 
surgery. Similarly, radiation therapy can be therapeutic and/or palliative 
in certain situations of localized disease. For patients with unresectable, 
localized disease not amenable to radiation therapy, local regional 
treatments such as hepatic artery infusion, chemoembolization, or 
radiofrequency ablation can be considered. At this time, the 
recommended follow-up consists of a history and physical examination 
every three to six months for three years, then yearly, and diagnostic 
tests as indicated by symptoms. 
Unlike other cancers that present with metastatic disease, the 
uncertainties surrounding the diagnosis of CUP and the grim prognosis 
can lead to significant psychosocial distress for both the patient and 
family. Early involvement of a palliative care team and/or oncology-
focused psychologist or psychiatrist can beneficially impact the patient 
and family as well as the entire team of health care providers by 
facilitating the many difficult transitions that CUP brings to all the lives 
that it disrupts.10 
 
Exceptions 
Three conditions, also called carcinoma of unknown primary, should be 
considered separately, essentially as different diseases, even though 
they are each labeled carcinoma of unknown primary, because the 
treatment and the prognosis of each is so different. 
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Cancer of Unknown Primary in the Neck (SCCUP) 
Nodes in the supraclavicular fossa most likely arise from the trunk, and 
are included in the above discussion. Squamous cell carcinoma 
(SCCUP) presenting above the clavicles is a different disease, with a far 
better prognosis, and is managed differently, with curative intent. There 
is even a separate NCCN guideline for SCCUP. This condition is 
managed primarily by otolaryngologists and radiation oncologists.9 
Cancer presenting in the mid to upper neck is most likely to be 
squamous cell carcinoma arising from the upper airodigestive tract. 
Patients with palpable nodes in the neck should be referred to qualified 
oncologic otolaryngologists for workup; no other physician should 
attempt biopsy. Location of nodes in the neck should direct initial 
physical examination. Posterior triangle nodes suggest involvement of 
the nasopharynx. Also, this is the only cancer of unknown primary in 
which PET scanning has been demonstrated to be effective in helping 
determine a primary site. It reveals the primary site in about 25% of 
patients (Figure 1). 
Figure 1. PET/CT Fusion axial images (1a-1d) and sagital and coronal images 
(1e & 1f) of patient with a PET+ necrotic node on right posterior triangle of the 
neck. Note entirely negative respiratory mucosa. University of Massachusetts 
Medical School, Department of Radiation Oncology. 
 
1a. Brain is hot, fusion between CT and PET is not perfect, even though the 
images were obtained on PET/CT machine. 
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The traditional paradigm for work-up of these patients requires 
panendoscopy with blind biopsies of nasopharynx, tonsils (perhaps with 
tonsillectomy) and base of tongue. The new paradigm for work- up of 
SCCUPs involves transoral robotic surgery. This procedure finds a 
primary malignancy in 70-90 % of patients, as opposed to 25% with the 
traditional examination under anesthesia and blind biopsies.11  
If office physical examination, including endoscopy, does not establish a 
primary site to biopsy, fine needle aspiration of the involved node is 
strongly preferred to open biopsy. Then panendoscopy, with biopsy of 
any suspicious lesions, and if none, tonsillectomy and blind biopsies of 
base of tongue, and nasopharynx are indicated. Pathology of the nodal 
disease may be revealing; lymphoepitheliomas usually arise in 
Waldeyer’s ring, and HPV infection patients have a better prognosis. And 
the precise location of the palpable nodal disease helps direct both the 
search for the primary and radiotherapy planning. For example, posterior 
triangle nodes are indicative of nasopharyngeal origin, so treatment of 
the larynx will not benefit the patient. 
Management of the neck is the same as for other head and neck 
squamous cell cancers- surgery +/- radiotherapy to the lymphatic 
volumes of the neck; but for SCCUP, treatment of most or all of the 
mucosa of the upper aerodigestive tract is indicated in an attempt to 
prevent later appearance of the primary. Finding a primary site allows for 
restriction of radiotherapy treatment volume; completely resecting an 
early primary may eliminate the need for radiotherapy to the mucosa. In 
both cases, shrinking the radiotherapy target dramatically decreases the 
risk of late xerostomia and dysphasia, improving quality of life. Hence, 
searching for the primary in a SCCUP is worthwhile. 
Treatment of the neck depends on the volume of disease. Small volume 
nodal disease may be managed with neck dissection or radiotherapy 
alone. Larger volume disease requires bimodality or trimodality therapy 
(see Principles of Multidisciplinary Management chapter). However, the 
role of chemotherapy in this disease remains unproven. Volume of tissue 
which should receive radiotherapy remains controversial; some advocate 
treatment of the entire upper aerodigestive tract. 
 
 
 
Outcome 
The NCI website reports 3 year disease free survival rates for SCCUP: 
40-50% for N1 disease, 38% for N2 and 26% for N3. Overall survival is 
significantly better. Patients who develop a head and neck primary tumor 
after a first course of treatment in this setting have a poorer outcome 
than those who do not. Unfortunately, many of these patients arrive at 
the otolaryngologist expecting the same prognosis as the other CUP 
patients. It is important that all physicians be aware of the difference 
between this disease and what is explained to in the rest of this chapter. 
Poorly differentiated carcinoma in the thoracic midline in a young male 
As noted previously in this chapter, most patients with carcinoma of 
unknown primary have a poor response to chemotherapy. However, in 
the 1980’s, clinical investigators recognized that men with midline, poorly 
differentiated carcinomas frequently did very well with cisplatin-based 
chemotherapy12. Although the tumors in these patients may not be 
recognizable as germ cell tumors, their location and response to 
chemotherapy is consistent with extra-gonadal germ cell tumors. Gain of 
the short arm of chromosome 12 (isochromosome 12p; i(12p)) is the 
most common chromosome abnormality seen in germ cell tumors and 
has been reported in midline poorly differentiated carcinomas in young 
men. These cancers may also express beta-human chorionic 
gonadotropin or alpha-fetoprotein. 
Axillary nodal metastases pathologically consistent with breast origin 
Occasionally a woman may present with axillary adenopathy without 
clinical or radiographic evidence of a primary breast cancer. If excision of 
the suspicious node shows an adenocarcinoma consistent with breast 
cancer, the tumor cells should also be studied for the presence of the 
estrogen receptor, progesterone receptor, and HER2. If pathologic and 
clinical evaluations suggest that the node involvement is likely due to 
breast cancer, the patient should be treated for breast cancer with 
appropriate surgery, radiation, hormonal therapy, and chemotherapy. 
Over half of these patients will enjoy prolonged survival. 
 
Conclusion 
Cancers of unknown primary (CUP) are metastatic tumors whose 
primary site cannot be determined after a standard diagnostic and 
Cancers of Unknown Primary 
 
 
Cancer Concepts: A Guidebook for the Non-Oncologist   (26 August 2015) 
6 
pathologic work-up. Most patients have a very poor prognosis, with the 
exception of the squamous cell carcinoma of the head and neck, axillary 
metastases pathologically consistent with breast origin, and 
undifferentiated carcinomas in the thoracic midline in young men, which 
behave like germ cell tumors. These three conditions should be 
considered different diseases than the usual carcinomas of unknown 
primary. 
For several years, there has been interest in whether genomic profiling of 
CUPs may allow identification of the site of origin of tumors, and if that 
identification would permit therapy targeted at that tumor type. Several 
laboratories in the United States now offer molecular testing of CUP 
samples. Whether molecular identification will lead to improved survival 
must await clinical trials.13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thought Questions 
1. How is it biologically possible for a cancer to spread widely 
throughout the body and yet not be able to identify the primary tumor 
site? Suggest three hypotheses that could explain this phenomenon. 
 
Your answer: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expert Answer 
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2. The "favorable" prognostic cancers listed in Points 1-6 in Table 1 
all share characteristics of specific known cancers. Which cancer 
does each of these clinical scenarios resemble? Why are they 
relatively "favorable"? 
 
Your answer: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expert Answer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Why is squamous cell carcinoma metastatic to cervical lymph nodes 
considered a different disease from other CUPs? 
 
Your answer: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expert Answer 
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Glossary 
Bimodality therapy– Treatment with any two of the three cancer 
treatment modalities– surgery, radiation therapy and chemotherapy 
Chemoembolization- Injection of chemotherapy and occlusive material 
into the artery feeding a tumor. This exposes the tumor to very high 
concentrations of chemotherapy and also obstructs arterial blood flow to 
the cancer and may infarct a cancer. 
Core needle biopsy- Removal of a tissue core into a large gauge needle 
Fine needle aspiration- Removal of a cellular aspirate from a tissue with 
a small gauge needle 
Gene expression profiling (GEP)- Analysis of mRNA expression of a 
tissue. Typical GEP will assess thousands of genes at a time. 
Hepatic artery infusion- Installation of material (e.g., chemotherapy) 
directly into the hepatic artery. Note that many cancers involving the liver 
obtain their principle blood supply from the hepatic artery, not the portal 
vein. 
Immunohistochemical (IHC) studies- Use of monoclonal antibodies 
directed against specific proteins expressed by cells to identify the 
presence of such proteins on or in cells. 
Incisional biopsy- Removal of tissue through a surgical incision 
Light microscopic examination- Review of a tissue specimen by light 
microscopy. 
Multivisceral- Metastases to more than one organ 
Radiofrequency ablation- Insertion of a radiofrequency probe into a 
tumor, followed by microwave heating of the tissue by the probe 
Regional treatments- Any treatment directed only at a specific body 
region. This contrasts with systemic therapies (e.g., drugs) which can 
reach virtually any part of the body. 
Trimodality therapy– Treatment with all three cancer treatment 
modalities– surgery, radiation therapy and chemotherapy 
Waldeyer’s ring– A ring of lymphatic tissue surrounding and protecting 
the upper airway– nasopharynx, lingual tonsils and base of tongue 
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